Cumulative effects of raloxifene on the incidence of breast cancer over 8 years in postmenopausal women with osteoporosis.

被引：0
|
作者：
Mershon, J.
Yea, A.
Qu, Y.
Wong, M.
Mitchell, B.
Vogel, V.
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Univ Pittsburgh, Pittsburgh, PA USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S180 / S180
页数：1
相关论文
共 50 条
  • [31] Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women receiving treatment for prevention or treatment of osteoporosis.
    Palacios, S
    Farias, ML
    Luebbert, H
    Gomez, G
    Yabur, JA
    Quail, DC
    Turbi, C
    Kayath, MJ
    Almeida, MJ
    Moennig, E
    Nickelsen, TN
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S272 - S272
  • [32] Effects of the Combined Therapy with Raloxifene and Low-Dose Intermittent Fluoride for Two Years in Postmenopausal Women with Osteoporosis
    Chung, Suk Mo
    Kim, Ghi Chan
    [J]. ANNALS OF REHABILITATION MEDICINE-ARM, 2007, 31 (02): : 207 - 212
  • [33] Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene
    Powles, Trevor J.
    Diem, Susan J.
    Fabian, Carol J.
    Neven, Patrick
    Wickerham, D. Lawrence
    Cox, David A.
    Muram, David
    Agnusdei, Donato
    Dowsett, Sherie A.
    Amewou-Atisso, Messan
    Cummings, Steven R.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 299 - 306
  • [34] Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene
    Trevor J. Powles
    Susan J. Diem
    Carol J. Fabian
    Patrick Neven
    D. Lawrence Wickerham
    David A. Cox
    David Muram
    Donato Agnusdei
    Sherie A. Dowsett
    Messan Amewou-Atisso
    Steven R. Cummings
    [J]. Breast Cancer Research and Treatment, 2012, 134 : 299 - 306
  • [35] Continuing outcomes relevant to evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene
    Martino, S
    Cauley, JA
    Barrett-Connor, E
    Powles, TJ
    Mershon, J
    Disch, D
    Secrest, RJ
    Cummings, SR
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (23) : 1751 - 1761
  • [36] Incidence of Invasive Breast Cancer in Postmenopausal Women After Discontinuation of Long-Term Raloxifene Administration
    Vogel, Victor G.
    Qu, Yongming
    Wong, Mayme
    Mitchell, Beth
    Mershon, John L.
    [J]. CLINICAL BREAST CANCER, 2009, 9 (01) : 45 - 50
  • [37] Incidence of breast cancer in postmenopausal women after discontinuation of long-term raloxifene use.
    Vogel, V.
    Qu, Y.
    Wong, M.
    Mitchell, B.
    Mershon, J.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S180 - S181
  • [38] Does raloxifene reduce postmenopausal women's risk of breast cancer?
    Han, RK
    Pimlott, N
    Heisey, R
    [J]. CANADIAN FAMILY PHYSICIAN, 2000, 46 : 77 - +
  • [39] Effect of raloxifene on invasive breast cancer incidence by baseline breast cancer risk in postmenopausal women at risk for major coronary events.
    Geiger, M. J.
    Song, J.
    Dowsett, S. A.
    Barrett-Connor, E.
    Cauley, J.
    Grady, D.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S169 - S169
  • [40] Risk factors for breast cancer in postmenopausal women with osteoporosis
    Cauley, J
    Cummings, S
    Song, J
    Dowsett, S
    Mershon, J
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 794 - 794
12345